Clinical Trial Update: Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update assessing long-term prophylaxis with ranolazine for congenital Long QT Syndrome Type 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Long Qt Syndrome Type 3

Drugs mentioned

• Ranolazine (ranolazine)

Snippet

Sponsor: Tel-Aviv Sourasky Medical Center | Conditions: Long QT Syndrome Type 3 | Phase 2 | Status: UNKNOWN